title: Anatomical hepatectomy for hepatocellular carcinoma in patients with preserved liver function.
abstract: OBJECTIVE
  This study aimed to clarify the efficacy of anatomical hepatectomy in patients with preserved liver function.
  
  
  METHODS
  We compared the clinicopathology of the anatomical hepatectomy (AH) group (n=264) with that of the non-anatomical hepatectomy (NAH) group (n=85) and evaluated favorable conditions of anatomical hepatectomy for patients with HCC with an indocyanine green 15-minute retention rate of less than 30%.
  
  
  RESULTS
  There was no significant difference between the two groups in five-year disease-free survival. However, disease-free survival of the AH group was significantly better than that of the NAH group when patients had T1 tumors, tumors without intrahepatic metastasis, tumors located within one subsegment, or serum alpha feto-protein less than 100 ng/dl (p=0.015, p=0.009, p=0.046 and p=0.036, respectively). Anatomical hepatectomy was an independent favorable prognostic factor by multivariate analysis taking into consideration clinical factors, which could be clarified pre- or intraoperatively (p=0.003).
  
  
  CONCLUSIONS
  Anatomical hepatectomy should be performed for HCC patients with HCC with preserved liver function.
authors.affiliation: Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan. tochiai@koto.kpu-m.ac.jp
authors.forename: Toshiya
authors.initials: T
authors.lastname: Ochiai
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ikoma
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Konishi
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Murayama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shiozaki
authors.forename: Shuhei
authors.initials: S
authors.lastname: Komatsu
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kuriu
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kubota
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Nakanishi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ichikawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Kazuma
authors.initials: K
authors.lastname: Okamoto
authors.forename: Eigo
authors.initials: E
authors.lastname: Otsuji
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000601:surgery*; D004396:Coloring Agents; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D007208:Indocyanine Green; D008099:Liver / Q000378:metabolism*; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D004396:Coloring Agents; D007208:Indocyanine Green